• Notifications
    This feature only available to registered users.
  • Alerts
    This feature only available to registered users
  • Welcome Guest!
  • Login Signup

Stock [ BUY ] / [ SELL ] Trading Strategies
. [ Show Details ]


Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
     
CVM [ CEL-SCI Corp ]
Last Trade 12.19 Date 8/8/2020
Change % -0.17 % Price Change -0.02
Open 12.07 52 Week High 18.0
High 12.3599 52 Week Low 6.0
Low 11.86 Type stock
Volume 251025 Average Volume 957937
Prev Close 12.21 Stock Exchange A
Bid 11.83 Ask 12.7
Bid Size 6 Ask Size 2
1st Yr Estimated EPS Growth 0.0602 2nd Yr Estimated EPS Growth
2 Years Forward Earning Yield 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 0.3244 Book Value Yield 0.0266
Buy Back Yield CAPE Ratio
Cash Return -0.0379 Cash Flow per Share -0.4759
Cash Flow Yield -0.039 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.0771 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue EV / Pre Tax Income
EV / Revenue EV / Total Asset 13.2052
Expected Dividend Growth Rate Free Cash Flow per Share -0.5011
Free Caash Flow Ratio Free Cash Flow Yield -0.0411
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.0673 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 37.576838 PB Ratio 10 Year Growth 0.287145
PB Ratio 3 Year Growth 6576.987661 Cash Ratio 3 Year Average 2788.1426
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 0.97442
Price to Cash Ratio 32.01405 Price / EBITDA
Price to Sales Ratio Price to Sales Ratio 10 Year Growth
Price to Sales Ratio 3 Year Avg Price to Sales Ratio 5 Year Avg
Sale per Share 0.0 Sales Yield 0.0
Sustainable Growth Rate -4.7769 Tangible Book Value per Share 0.3161
Tangible Book Value per Share 3 year Avg -0.0479 Tangible Book Value per Share 5 year Avg -0.2727
Total Asset per Share 0.9225 Total Yield
Working Capital per Share 0.28 Working Capital per Share 3 Year Avg -0.0767
Working Capital per Share 5 Year Avg 0.0793 Beta 3.194842
Company Profile

CEL-SCI Corporation engages in the research and development of drugs and vaccines used in the treatment of cancer. Its lead product includes Multikine, which is under development for the treatment of cancer and is cleared for a Phase III clinical trial in advanced primary head and neck cancer patients. Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines, and colony-stimulating factors. The company is also developing CEL-1000, which is derived from a pre-clinical technology called ?Ligand Epitope Antigen Presentation System? to stimulate the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer; and CEL-2000 for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia.